KR20240022560A - 바이러스 감염의 신경학적 합병증의 치료 및 예방을 위한 신규 화합물 - Google Patents

바이러스 감염의 신경학적 합병증의 치료 및 예방을 위한 신규 화합물 Download PDF

Info

Publication number
KR20240022560A
KR20240022560A KR1020247001041A KR20247001041A KR20240022560A KR 20240022560 A KR20240022560 A KR 20240022560A KR 1020247001041 A KR1020247001041 A KR 1020247001041A KR 20247001041 A KR20247001041 A KR 20247001041A KR 20240022560 A KR20240022560 A KR 20240022560A
Authority
KR
South Korea
Prior art keywords
compound
ophioglossum
metabolite
pharmaceutical composition
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247001041A
Other languages
English (en)
Korean (ko)
Inventor
유홍 동
Original Assignee
썬리겐 헬쓰케어 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 썬리겐 헬쓰케어 아게 filed Critical 썬리겐 헬쓰케어 아게
Publication of KR20240022560A publication Critical patent/KR20240022560A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020247001041A 2021-06-18 2022-06-17 바이러스 감염의 신경학적 합병증의 치료 및 예방을 위한 신규 화합물 Pending KR20240022560A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21180462.0 2021-06-18
EP21180462 2021-06-18
PCT/EP2022/066548 WO2022263624A1 (en) 2021-06-18 2022-06-17 Novel compounds for the treatment and prevention of neurological complications of viral infections

Publications (1)

Publication Number Publication Date
KR20240022560A true KR20240022560A (ko) 2024-02-20

Family

ID=76532115

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001041A Pending KR20240022560A (ko) 2021-06-18 2022-06-17 바이러스 감염의 신경학적 합병증의 치료 및 예방을 위한 신규 화합물

Country Status (6)

Country Link
US (1) US20240307339A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355316A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024523429A (cg-RX-API-DMAC7.html)
KR (1) KR20240022560A (cg-RX-API-DMAC7.html)
CN (1) CN117529311A (cg-RX-API-DMAC7.html)
WO (1) WO2022263624A1 (cg-RX-API-DMAC7.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150125A (en) * 1977-09-30 1979-04-17 Abbott Laboratories Triglyceride ester of phosphonoacetic acid having antiviral activity
JP2000007581A (ja) * 1998-06-18 2000-01-11 Nippon Kayaku Co Ltd 抗ウイルススプレー剤
KR20120129898A (ko) * 2009-12-30 2012-11-28 베일러 리서치 인스티튜트 알츠하이머 질환 및 노화 뇌를 위한 보충대사 치료요법
CN104940589A (zh) * 2015-06-18 2015-09-30 王峰 治疗急性结膜炎的中药制剂及制法
NZ749389A (en) * 2016-06-08 2022-12-23 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
WO2018159941A1 (ko) * 2017-03-02 2018-09-07 대화제약 주식회사 자나미비르를 포함하는 안정한 약제학적 조성물
KR101991661B1 (ko) * 2017-03-02 2019-06-21 대화제약 주식회사 자나미비르를 포함하는 안정한 약제학적 조성물
WO2019052629A1 (en) * 2017-09-12 2019-03-21 Sunregen Healthcare Ag LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT

Also Published As

Publication number Publication date
WO2022263624A1 (en) 2022-12-22
US20240307339A1 (en) 2024-09-19
CN117529311A (zh) 2024-02-06
JP2024523429A (ja) 2024-06-28
EP4355316A1 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
Wang et al. Simvastatin prevents β-amyloid25–35-impaired neurogenesis in hippocampal dentate gyrus through α7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate
Uthayathas Versatile effects of sildenafil: recent pharmacological applications
Tsubura et al. Animal models for retinitis pigmentosa induced by MNU; disease progression, mechanisms and therapeutic trials
Sun et al. Dexmedetomidine exerts a protective effect on ischemic brain injury by inhibiting the P2X7R/NLRP3/Caspase-1 signaling pathway
CN110300581B (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
Kang et al. Roots of Lithospermum erythrorhizon promotes retinal cell survival in optic nerve crush-induced retinal degeneration
US20230078820A1 (en) Fenfluramine for treatment of demyelinating diseases and conditions
WO2018113027A1 (zh) 白果内酯作为增效剂在制备防治脑神经损伤性疾病药物的应用
Wareham et al. Increased bioavailability of cyclic guanylate monophosphate prevents retinal ganglion cell degeneration
US20210317455A1 (en) Inhibitor of tdp-43 aggregation
JP5783377B2 (ja) 網膜色素変性症を予防する及び遅発させるためのセリンパルミトイルトランスフェラーゼ阻害剤
Salama et al. Naringin attenuates D-galactose-induced brain aging via regulation of oxidative stress markers TNF-α, NF-κβ and modulation of the neurotrophic markers PGC1-α, NT-3 AGEs, and GFAP in vivo
KR20160012184A (ko) 뉴런 세포에서의 단백질 응집체 침착을 특징으로 하는 질환을 치료하는데 사용하기 위한 타크롤리무스
Lee et al. The effects of Korean Red Ginseng-derived components on oligodendrocyte lineage cells: Distinct facilitatory roles of the non-saponin and saponin fractions, and Rb1, in proliferation, differentiation and myelination
US20240307339A1 (en) Novel compounds for the treatment and prevention of neurological complications of viral infections
US20160354392A1 (en) Mitochondria-targeted antioxidants for treatment of age-related brain disorders
Belayev et al. LAU-0901, a novel platelet-activating factor receptor antagonist, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat
JP2020007376A (ja) リポカリン型プロスタグランジンd2合成酵素産生促進剤
Efimenko et al. Studies to elucidate the effect and antiapop-totic mechanism of 2-ethyl-3-hydroxy-6-methylpyridine-n-acetyltaurinate in a rat model of retinal ischemia–reperfusion
CN106074585A (zh) 人参皂苷Rb1和Rd组合及其在制备治疗光感受器细胞死亡相关疾病的药物中的应用
TWI587860B (zh) 喹啉衍生化合物用於製備Tau蛋白病變類疾病之醫藥組成物上之用途
HK40021759B (en) Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
US20230398088A1 (en) Lipid Prophylactic Brain Injury Treatment
TWI650121B (zh) 化合物用於製備Tau蛋白病變類疾病之醫藥組成物上之用途
Li et al. Stimulation of Thyroid Hormone Signaling Induces Stress

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902